This article is more than 5 years old. Information may no longer be current.

GnRH analogue failed to preserve post-treatment ovarian function

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

New data indicate that administration of a gonadotropin-releasing hormone analogue did not maintain ovarian function in women at risk for developing ovarian insufficiency related to breast cancer treatment, according to findings presented at the American Society for Reproductive Medicine 67th Annual Meeting.

Researchers at the Zagazig University School of Medicine and the Alexandria Regional Center for Women Health and Development in Egypt conducted a multicenter trial to evaluate the potential benefit of gonadotropin-releasing hormone (GnRH) in 100 women aged 18 to 37 years who were to receive cyclophosphamide-based chemotherapy for breast cancer. The researchers randomly assigned women who were to initiate treatment 4 to 7 days after presentation to immediately receive a GnRH-agonist or a GnRH-antagonist followed 3 days later by a 7-day course of chemotherapy (Arm I) or chemotherapy with placebo (Arm II). The researchers also randomly assigned women who were to begin treatment at least 10 days after presentation to immediately receive a GnRH-agonist followed 10 to 14 days later by chemotherapy (Arm III) or chemotherapy plus placebo (Arm IV). Administration of GnRH continued throughout treatment.

Results revealed that menses resumed for 64% of patients in Arm I compared with 72% of patients in Arm II at 6 month (P>.05). At 12 months, 80% of patients in each group had resumed menses, according to the researchers. For patients who received later treatment, menses resumed for 68% of patients at 6 months and 84% at 12 months in Arm III compared with 76% and 80% in Arm IV (P>.05). The researchers noted no statistically significant differences in hormonal levels between Arms I and II or Arms III and IV at either time point (P>.05).

“GnRH analogue administration before and during cyclophosphamide-based chemotherapy for young women with breast cancer does not appear to preserve post-treatment ovarian function,” the researchers wrote.

Earn CME this spring at the HemOnc Today Breast Cancer Review & Perspective meeting to be held March 23-24, 2012 at the Hilton San Diego Bayfront. See details at HemOncTodayBreastCancer.com.

For more information:

• Elgindy EA. O-158. Presented at: the American Society for Reproductive Medicine 67th Annual Meeting; Oct. 15-19, 2011; Orlando, Fla.

Follow HemOncToday.com on Twitter.